Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14 août 2024 16h16 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
13 août 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Clinical Trial Results at the
2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
12 août 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
08 août 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
25 juil. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs
at 2024 SNO/ASCO Conference
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
02 juil. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
07 juin 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Plus Therapeutics Announces New Employment Inducement Grants
17 mai 2024 17h00 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants